GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Cheng Yi Pharmaceutical Co Ltd (SHSE:603811) » Definitions » Liabilities-to-Assets

Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Liabilities-to-Assets : 0.35 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zhejiang Cheng Yi Pharmaceutical Co Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Zhejiang Cheng Yi Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥647.9 Mil. Zhejiang Cheng Yi Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 was ¥1,877.3 Mil. Therefore, Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.35.


Zhejiang Cheng Yi Pharmaceutical Co Liabilities-to-Assets Historical Data

The historical data trend for Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Cheng Yi Pharmaceutical Co Liabilities-to-Assets Chart

Zhejiang Cheng Yi Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.27 0.25 0.37 0.37

Zhejiang Cheng Yi Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.37 0.37 0.37 0.35

Competitive Comparison of Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets falls into.



Zhejiang Cheng Yi Pharmaceutical Co Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=696.154/1892.766
=0.37

Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=647.945/1877.301
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Cheng Yi Pharmaceutical Co  (SHSE:603811) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Zhejiang Cheng Yi Pharmaceutical Co Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Zhejiang Cheng Yi Pharmaceutical Co's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Business Description

Traded in Other Exchanges
N/A
Address
No. 118, Chemical Road, Dongtou District, Zhejiang Province, Wenzhou, CHN, 325700
Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.
Executives
Ke Ze Hui Director
Ren Bing Jun Director
Yan Yi Yi Director
Ceng Huan Qun Director
Li Shi Sheng Director
Qiu Ke Rong Director
Lv Sun Zhan senior management
Zhang Gao Qiao Supervisors
Zhang Zhi Hong senior management
Mao Li Ping senior management
Zhuang Xiao Ping Director
Lin Xin Chen senior management
Shen Ai Lan Director
Zhang Fu Fu Supervisors

Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Headlines

No Headlines